GENFIT hires Thomas Baetz as Chief Financial Officer and adds two new members to its Executive Committee - Seite 2

Stefanie Magner, also joins the Executive Committee as Chief Compliance Officer and VP International Legal Affairs, position she holds since March 1, 2021. She joined GENFIT in 2016 as Deputy Director of Legal Affairs, after working as a lawyer for nearly 10 years at the Paris offices of the global U.S. law firm, Jones Day. Advising issuers and investment banks, she acquired significant experience in the financing of biotech companies, working on a variety of corporate, cross-border securities and M&A transactions, including several IPOs. She actively participated in GENFIT’s Nasdaq IPO in 2019.

Admitted to practice law in New York and a former member of the Paris Bar, she holds a BA in International Relations and French from the University of Pennsylvania (including a year at Sciences-Po Paris), and U.S and French law degrees from the American University in Washington D.C. and the Université de Paris X – Nanterre.

Pascal Prigent, CEO of GENFIT, added: “We are delighted to welcome Thomas as the CFO of GENFIT. His international experience will be useful to continue our expansion and finance our growth. I also welcome Stefanie to the Executive Committee, with compliance becoming an increasingly important subject as we get closer to a potential commercialization in the US. Her expertise in international finance has also been crucial during our IPO on the Nasdaq in 2019.”

ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently enrolling in ELATIVE, a Phase 3 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC). Elafibranor is an investigational compound that has not been reviewed and has not received approval by any regulatory authority. As part of GENFIT’s comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4, a new, non-invasive blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH. NIS4 technology has been licensed to LabCorp in the U.S. and Canada for the development and commercialization of a blood-based molecular diagnostic test powered by NIS4 technology. GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com